Steini, in this case the $300m buyout was of a somewhat...

Steini, in this case the $300m buyout was of a somewhat disadvantaged
company whose main researchers were probably happy to go along
for the ride....In short, they were happy to be taken over...
I'm not sure Imugen research scientists would be happy to be usurped
into a conglomerate and basically just be numbers.....
Axel and Leslie would be prime requirements for any takeover to
be agreed to, not sure how they would react....
Merck, for example, explaining their recent M&A record of doing little
put some of the blame on desired targets not being will to sell....